Korea OKs first cell gene therapy ‘Invossa’ – The Korea Herald
The Korea Herald |
Korea OKs first cell gene therapy ‘Invossa’
The Korea Herald Korea’s Ministry of Food and Drug Safety has granted approval to Invossa-K Inj., an injectable cell gene therapy for osteoarthritis, a joint disease common among the elderly in which the cartilage that cushions the ends of bones between joints breaks down. |
TheStreet.com |
Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday
TheStreet.com The Oncologic Drugs Advisory Committee will examine the safety of CAR T-cell treatments, an immunotherapy manufactured by Novartis AG (NVS) for treatment of children and young adult leukemia patients who have not responded to traditional treatments. Novartis readies for FDA review of $1 billion CAR-T child cancer hopeReuters UK Novartis dodged deaths from its CAR-T Therapy, but FDA still has safety concernsLabiotech.eu (blog) Novartis’ CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory PanelAJMC.com Managed Markets Network |
Korea Biomedical Review |
Ministry approves 1st domestic gene therapy product
Korea Biomedical Review The Ministry of Food and Drug Safety said Wednesday it granted approval to Kolon’s gene therapy for knee osteoarthritis as the 29th domestically produced drug to gain approval and as the first of its kind. |
|
Immunotherapy offers hope to lung cancer patients
Jakarta Post Immunotherapy offers hope to lung cancer patients Courtesy of dongyminhngoc.org” width=”780″ height=”607″ border=”0″>Courtesy of dongyminhngoc.org. The prognosis of lung cancer patients remains the worst of all, with an average survival time of only … |